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Background: The primary objective was to estimate the national burden of illness in Canada for diabetic foot ulcer
(DFU) for 2011. Secondary objectives included estimating the national incidence and prevalence of DFU, and the
3-year average cost for DFU incident cases.
Methods: Analyses were conducted using four national databases for the period April 1, 2006 to March 31, 2011,
with cases being identified by ICD-10 CA codes. Resource utilization and costs, expressed in 2011 Canadian dollars,
were estimated for DFU-related hospitalizations, emergency care (ER), same day surgeries, home care, long term
care, physician visits and caregiver time losses.
Results: In Canada in the year 2011, DFU was associated with 16,883 hospital admissions (327,140 days), 31,095 ER
or clinic visits, 41,367 rehabilitation clinic visits, and 26,493 interventions, including 6,036 amputations and 5,796
surgical debridements. This acute institution care represented $320.5 M, and with an additional $125.4 M for home
care and $63.1 M for long term care, the annual cost associated with DFU-related care was $547.0 M, or $21,371
annual cost per prevalent case. In 2011, the national prevalence of DFU was 25,597 cases (75.1 per 100,000 population),
consisting of 16,161 men (63.1%) and 9,436 women (36.9%), and an estimated 14,449 incident cases. For an incident
case of DFU, the average 3-year cumulative cost was $52,360.
Conclusion: The annual burden for DFU cases that have at least one admission or ER/clinic visit over a 5 year period is
higher than previously reported.
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Diabetes is one of the most costly and burdensome
chronic diseases [1]. The economic burden of diabetes
in Canada was estimated at $12.2 billion in 2010 and is
expected to rise by another $4.7 billion by 2020 [2]. The
direct cost of diabetes accounted for 3.5% of all public
healthcare spending in Canada in the year 2005 [2].
A major concern with diabetes is the high risk of having
one of many major complications such as cardiovascular,
i.e., myocardial infarction, stroke, angina, or heart failure,
or other types of complications such as blindness, ampu-
tation, or nephropathy [3]. Less emphasis has been placed* Correspondence: hopkinr@mcmaster.ca
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unless otherwise stated.on diabetic foot ulcers (DFU), even though they are one of
the most devastating complications of diabetes [2]. Out of
2.7 million Canadians living with diabetes in 2010 [2], the
probability of developing a DFU in their lifetime was 15
percent [2,4]. DFUs are caused by poor circulation associ-
ated with peripheral neuropathy and peripheral vascular
disease, and if unnoticed and without early treatment, a
DFU may become infected and persistent (chronic), which
can lead to amputation and death [5]. Diabetic foot
infections are the most common reason for admission
to hospital for Canadians living with diabetes [2], and
an estimated 85% of all amputations in people with
diabetes are the result of a non-healing DFU [2].
In order to estimate the impact that DFU has on the
health care budget and society, a current estimate of the
number of new and existing cases as well as the cost per
case are required. Two previous estimates were available
for Canada. In the first estimate, the hospital budget costl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Additional costs of $17,130 for an amputation, as well as
separate costs for neuropathy, prosthesis, gangrene were
listed but were not pooled for an average cost per
patient [6]. The second estimate which was reported as
an average cost per patient included hospital admission,
physician billings including procedures, but did not
include supportive home care and long term care (LTC).
The average cost for a patient with DFU was $2,183 in
the first year, with zero care in subsequent years [7].
However, these estimates only include the cost of a
single admission with a single emergency room (ER) visit,
and exclude the costs of amputation, chronic care such as
home care, LTC, wound or supportive dressings, and asso-
ciated physician visits. In addition, the number of new and
existing DFU cases has not been tracked over a multi-year
period to establish prevalence and incidence.
The primary objective of this study was to estimate
the national economic burden of illness in Canada for
DFU for 2011. Secondary objectives included estimating
the national incidence and prevalence of DFU, and the
3-year average cost for incident DFU cases.
Methods
Overview
First, the national rates of prevalence and incidence of
DFU were estimated through an investigation of linked
databases over a 5-year period. Secondly, we estimated
the national resource utilization and costs for identified
prevalent cases of DFU. Finally, the average 3-year cost
was estimated for an incident case of DFU.
The analysis was conducted using standardized man-
datory national health administrative databases for
hospital admissions across Canada and available provincial
data for ER and clinic visits, home care and LTC facilities.
All costs were presented in 2011 Canadian dollars from a
payer perspective plus additional caregiver costs. For the
purpose of this research, the payer perspective includes
total direct healthcare costs to public payers: hospital
budget, physician fees, drugs in home care and LTC
setting for infections, wounds and supportive dressings,
wages for home care and LTC. The caregiver costs further
included the cost of time loss for the caregiver of a patient
experiencing DFU. The incident cohort analysis was
identified within the province of Ontario (population 13
million, 38% of the country), primarily because of the
comprehensiveness of its data coverage.
Data sources
Four linked databases from the Canadian Institute for
Health Information (CIHI) were used to gather Canadian
provincial data on acute care admissions (Discharge
Abstract Database – DAD) [8], emergency visits (National
Ambulatory Care Reporting System - NACRS) [9], sameday surgery (NACRS for Ontario, DAD for rest of
Canada), home care for Ontario (Home Care Reporting
System - HCRS) [10], and LTC for Ontario (Continuing
Care Reporting System – CCRS) [11]. These databases
were linked at the patient level to allow for the identifi-
cation of unique patients, while each data source has
different data elements which are briefly explained
below. Ethics approval was not required to receive data
from the retrospective database, consistent with CIHI
policy.
To provide national estimates, 2 extrapolations were
conducted due to data gaps in comprehensiveness of
data within some provinces and because of the absence
of data from 2 provinces. First, only Ontario had
mandatory reporting in NACRS for ER and clinic visits.
The extra number of cases identified in ER and clinic
visits, beyond admissions alone, as well as the health
care resource utilization for ER and clinic visits were
both extrapolated to other provinces based on age and
sex using Census data [12]. Specifically, for every age
group by 10 years and by sex, we estimated the incremen-
tal cases and resource utilization that occurred beyond ad-
mission data alone. We then applied this incremental
percentage to provinces without ER and clinic visit data.
A second extrapolation was necessary for the absence of
any data for Quebec and British Columbia (41% of coun-
try). We estimated the rate of incidence, prevalence and
resource utilization by age groups of 10 years and sex that
occurred in other provinces and applied these rates to the
size of the population for each age group and sex cohort
in Quebec and British Columbia to predict their provincial
estimates.
Admissions
The DAD captures mandatory information on every acute
care admission across Canada, and same day surgery
(excluding Ontario). The data from British Columbia
and Quebec were not available at the time of this research
due to the provincial privacy approval process. Each pa-
tient admission has a unique record and provides ICD-10
CA codes for ‘most responsible diagnosis’, which is the
diagnosis that results in the most resource intensity or
contributes to the longest length of stay (LOS). In
addition, up to 24 other ICD-10 codes are captured for
comorbidities and secondary diagnoses, as well as up to
20 intervention codes (surgical or diagnostic).
Emergency room and clinic visits
The NACRS database includes 100% coverage for all of
Ontario’s ER visits, hospital-based ambulatory care (i.e.
same day surgery) and hospital-based clinics, such as renal
dialysis or rehabilitation. Similar to DAD, the NACRS has
a unique record for each patient visit and includes up to
10 diagnostic codes and 10 interventions. In addition,
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patient before and after the admission, which allows track-
ing to home care, LTC or death.
Home care and long term care in Ontario
Data for home care (HCRS) and LTC (CCRS) includes
assessments completed at several time points: admission,
quarterly and with a change in patient’s clinical status.
Both home care and LTC assessments are conducted
with the InterRai Minimum Data Set (MDS) [13], which
covers more than 200 questions with categories for func-
tional limitations such as mobility status, daily activity
limitations, quality of life, and wound management, etc.
Data capture
Cases of DFU were identified using relevant ICD-10-CA
codes E1^.70 and E1^.71 (further details in Additional
file 1: Table S1). The data capture included all cases in
Canada (with the exception of Quebec and British
Columbia) that, at any time over the 5-year period (fiscal
years 2006/2007 to 2010/2011 (i.e. April 1, 2006 to
March 31, 2011)), had at least one ICD-10-CA diagnosis
code for DFU as the most responsible diagnosis, comor-
bidity or secondary diagnosis for an admission, or in
Ontario an ER or clinic visit. Data for home care and
LTC do not include ICD codes and could not be used to
identify cases with high sensitivity. After selecting all
cases, all admissions/visits, home care and LTC assess-
ments were captured for the 5-year period. The data
capture does not include DFU cases that did not have an
admission or ER/clinic visit over the 5 year period, such
as possibly Wagner grade 1 or early grade 2.
Prevalence and incidence
An incident case was identified as being incident in its
first year that a DFU code appeared, with the two previ-
ous years not having a DFU code. The total number of
unique cases by year and rates per 100,000 population
were reported as prevalent cases if a DFU diagnosis code
appeared during that year. As a sensitivity analysis for
prevalence we included cases that had DFU-related
events for up to 4 years after the first DFU code but did
not have a DFU code in the subsequent years. If a subse-
quent DFU-related event occurred even without a DFU
code the case was considered prevalent in the sensitivity
analysis only.
Resource utilization and costs of DFU
To estimate the frequency of hospitalizations, ER visits
and same day surgeries attributable to DFU, the ICD-10
codes for the most responsible diagnosis were summa-
rized for all admissions/visits by the selected cases. Then,
the types of outcomes (admissions/visits) were adjudicated
as related or not related, based on independent clinicalexpert guidance (1 wound care specialist, 1 wound care
nurse) and 1 vascular surgeon (JH). For example, admis-
sions for amputation or infection in the foot were consid-
ered related to DFU, whereas admissions for hemodialysis
or cancer care were considered not related. To estimate
the costs associated with hospitalizations, ER visits and
same day surgeries, unit costs were applied to the resource
utilization measured as relative resource intensity weight
(RIW) (See Additional file 1: Table S2 for the unit costs,
data sources, and main costing assumptions). The RIW
for all admissions/visits are estimated by CIHI, where the
value of 1.0 unit represents the average resource intensity.
The national unit cost per RIW for 2011 ($5,232 per unit
RIW) was multiplied to represent the costs in dollars. In
addition, the RIW only captures the hospital budget por-
tion of an admission/visit. Provincial physician billing fees
that occur any time during the admission period were
added to capture the cost for surgical procedures (e.g. sur-
geons, surgical assistants, anesthesiologists, and radiolo-
gists), diagnostic tests and daily assessments in hospital.
Admissions, ER or clinic visits that were included were
‘DFU’, ‘DFU with gangrene’, cellulitis, infection, osteomye-
litis, ‘complications with procedure’, ‘complications with
amputation’, rehabilitation, palliative care, convalescence,
‘peripheral angiopathy’ and ‘peripheral tissue problem’.
The admissions/visits were only included if there was a
DFU-related intervention (see Additional file 1: Table S4,
Additional file 1: Table S5). For example, for the admis-
sions for ‘peripheral tissue problem, 43% included an am-
putation and 43% included a debridement for a foot ulcer.
To estimate the costs associated with home care, the
MDS InterRai assessments captured the duration of
home care (time between first and last assessment), and
the level of care identified by case mix group. Each
assessment also enquires about health care resource
utilization in the last 7 days including indication for
infections, dressing changes, doctor and clinic visits, and
caregiver support. For each of these cost drivers, the unit
costs were applied to estimate total cost. Similar meth-
odology was used for estimating the costs of LTC, with
the only difference in methodology between home care
and LTC being the different resource intensity (by case
group) weighted cost per day. The costs of an antibiotic
regimen and the average cost per day of dressings were
obtained from the Ontario Ministry of Health and Long
Term Care [14]. The cost of doctor and clinic visits were
applied from the Ontario physician fee schedule, and the
value of caregiver time wage loss were valued at the
average national wage. To isolate the cost of DFU from
other types of wound care, the costs for home care and
LTC were estimated for cases that only had a stasis ulcer
(which includes DFU) and excluded cases that required
wound care for pressure ulcers and other types of skin
conditions (e.g. burns, cutaneous lesions other than ulcers,
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tural/fungi).
Incident cohort analysis
The incident cohort for FY2008/2009 was followed for a
total of 3 years (incident year plus 2 subsequent years).
For each of the years, the rates of admissions, visits and
procedures were captured. In addition, the proportion of
the incident cohort that required the use of home care,
the use of wound care in LTC by existing long term resi-
dents, and the number of cases that transitioned into
LTC were captured. The cost per year was estimated and
was reported as a 3-year cumulative cost.
Results
Data capture and identification of cases
The cases that reported an ICD-10 code for ‘DFU’ or
‘DFU with gangrene’ as most responsible diagnosis rep-
resented 60% of cases identified. The remaining 40% of
cases were identified with DFU as a comorbidity. In On-
tario, 12% of cases were identified only with ER and
clinic visits. For provinces that did not have ER and
clinic visit databases, results were increased by 12% to
account for these incremental cases. From these estimates,
the cases in Quebec and British Columbia were then
extrapolated based on estimates from the rest of the
country.
Prevalence and incidence
The estimated national number of prevalent cases in-
creased from 19,740 in 2007 to 25,597 in the year 2011,
which represents an increase of 29.7% (7.4% per year)
over the 5-year period. The prevalent rate for Canada in
2011 was 75.1 per 100,000 general population (0.075%).
The most common age group for cases was 55 to
64 years, while the highest prevalent rate was in the 75
to 84 years age group (Table 1). The cases were 63%
men (95.5 per 100,000) and 37% women (54.9 per
100,000). The rate varied from 64.7 in Ontario to 106.2Table 1 Prevalent and incident cases based on DFU code, by
Age group Prevalent cases (rates per 100,000)
Women Men All
<35 years 278 (3.8) 357 (4.7) 635 (4.3
35 to 44 years 606 (25.9) 1,065 (44.9) 1,671 (3
45 to 54 years 1,383 (51.2) 2,738 (101.0) 4,121 (7
55 to 64 years 2,180 (101.1) 4,478 (213.9) 6,666 (1
65 to 74 years 2,097 (156.3) 4,060 (329.5) 6,157 (2
75 to 84 years 2,031 (224.5) 2,861 (411.1) 4,892 (3
85+ years 853 (198.2) 602 (288.5) 1,455 (2
Total 9,436 (54.9) 16,161 (95.5) 25,597
DFU: Diabetic Foot Ulcer.in Manitoba. Most provinces reported a rate of 70 to 90
per 100,000 population (Additional file 1: Table S3).
The national incidence of DFU was 14,449 cases for
both women and men in 2011 (Table 1). Most of the
cases were men (61%), while the rate per 100,000 popu-
lation was 32.5 for women and 52.4 for men, with age
distributions similar to prevalent cases. The rates of inci-
dence ranged from 36.9 in Ontario to 57.2 in Manitoba,
while most provinces varied from 40 to 60 per 100,000
population (Additional file 1: Table S3).
In a sensitivity analysis on the estimate of prevalence,
34% had an admission, ER, clinic visit, or a procedure
that was consistent with DFU in the year after the inci-
dent index year, despite not having a DFU code in these
subsequent years. In the third year, 24% still had care
relevant to DFU, while in the fourth year 21% still had
relevant care, regardless of a specific DFU code. Based
on having relevant care after a DFU code, there were
3,989 additional cases in the year 2011, 15.6% higher
than with DFU code alone. Nationally, that translates
into 29,586 prevalent cases of DFU instead of 25,597.
Resource utilization and costs of DFU
The number of admissions related to DFU in 2011 was
16,863 (Table 2). Men accounted for 67% of the admis-
sions, and the average number of admissions per prevalent
case was 0.66 (SD = 0.98, median = 1, min = 0, max = 9).
The most common admissions were for ‘peripheral angio-
pathy’ (25%) or admissions coded as ‘DFU’ (18%) or ‘DFU
with gangrene’ (17%). The 16,863 admissions in 2011 rep-
resent 327,140 hospital bed days.
The estimated number of ER or clinic visits related to
DFU was 72,462 in 2011, which included 41,367 rehabili-
tation clinic visits and 31,095 non-rehab ER visits (Table 2).
This represents an average of 2.83 combined annual
ER or clinic visits, of which on average 1.62 (SD = 8.01,
median = 1, min = 0, max = 144) were rehabilitation and
1.21 (SD = 2.42, median = 1, min = 0, max = 71) were non-
rehabilitation. Excluding rehabilitation, the most commonage group and sex, Canada, 2011
Incident cases (rates per 100,000)
Women Men All
) 164 (2.2) 197 (2.6) 361 (2.4)
5.4) 314 (13.4) 524 (22.1) 838 (17.8)
6.1) 738 (27.3) 1,380 (50.9) 2,118 (39.1)
56.6) 1,171 (54.1) 2,277 (108.8) 3,448 (81.0)
39.2) 1,252 (93.3) 2,298 (186.5) 3,550 (137.9)
05.7) 1,317 (145.6) 1,775 (255.0) 3,092 (193.2)
27.7) 626 (145.4) 416 (199.4) 1,042 (163.0)
(75.1) 5,582 (32.5) 8,867 (52.4) 14,449 (42.4)
Table 2 Admissions and emergency/clinic visits related to DFU, by sex, Canada, 2011
Most responsible diagnosis Admissions ER and clinic visits
Women Men All Women Men All
DFU 881 2,134 3,015 2,827 6,380 9,207
DFU with gangrene 832 2,051 2,883 490 1,110 1,600
Infection/ sepsis 265 405 670 264 532 796
Cellulitis lower limb 744 1,103 1,847 3,630 6,277 9,907
Ulcer lower limb 160 209 369 101 187 288
Osteomyelitis 302 627 929 253 1,035 1,288
Complications with procedures 117 293 410 437 882 1,319
Complications with amputations 133 345 478 60 234 294
Surgical dressing care 1309 2220 3,529
Rehabilitation 195 435 630 11,435 29,932 41,367
Palliative care 61 73 134 0 30 30
Convalescence 209 484 693 3 9 12
Peripheral angiopathy 1,462 2,772 4,234 742 1,486 2,228
Peripheral tissue problems 202 369 571 179 418 597
Total 5,563 11,300 16,863 21,730 50,732 72,462
Total (less rehabilitation clinic) 10,295 20,800 31,095
DFU: Diabetic Foot Ulcer, ER: Emergency Room.
Table 3 Summary of burden of illness of DFU in Canada




Prevalence rates per 100,000 75.1
Incident cases 14,449






Cost: $ millions (2011 CAD$)





Long term care – current residents $51.7
Long term care – new residents $11.4
Total cost $547.0
Average cost per prevalent case $21,371
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‘DFU’ (30%).
The estimated number of interventions associated with
DFU was 26,493 in the year 2011, with 69% performed
in men. The interventions included 6,036 unique cases
with amputation (24% of interventions), 5,796 with surgi-
cal debridement (24%) and 6,663 with antibiotics (intra-
venous or injectable) (26%), 1,550 angioplasty of the leg
(6%), and 1,033 femoropopliteal bypass of the leg (4%)
(Additional file 1: Table S6). Of the 6,036 cases of amputa-
tion, 2,051 were tarsal, metatarsal, or ankle (fore, mid and
hind foot), and 2,011 were below the knee (tibia-fibula).
(Average costs per admission, emergency and clinic visits,
and interventions are provided in Additional file 1:
Table S7, Additional file 1: Table S8).
The rate of admissions varied across the provinces
by +/− 11% for women and +/−8% for men. Rates of
hospitalizations were higher in the prairie provinces
(Manitoba and Saskatchewan) and lower in the maritime
provinces (New Brunswick, Nova Scotia, Prince Edward
Island, and Newfoundland and Labrador).
In 2011 the resource utilization associated with DFU for
acute institutional care was $358.6 M, of which $320.5 M
was for admissions (89%), $19.1 M for ER and clinic visits
(5%), and an additional $19.0 M for interventions (5%)
(Table 3). If we had included admissions/visits that did not
have a DFU-related intervention, the cost of acute care
would be 17% higher.
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There were 1,808 DFU cases with repeated home care
assessment that did not include pressure ulcers or other
skin conditions, with a mean duration of home care of
238 days (average age of 70 years; 62% male). The aver-
age cost per home care case was $9,934, which consisted
of $3,948 for dressings, $38 for oral and IV antibiotics,
$739 for physician and clinic visits, and $5,209 for the
home care (wages and benefits of staff ). In addition, the
dollar value of time loss for a caregiver was on average
$12,432, resulting in a total home care cost of $22,366
per case with DFU.
There were 461 DFU cases that had repeated assess-
ments for LTC that did not include pressure ulcers and
other skin conditions. The average age was 78 years,
49% men, and the average duration of LTC was 110 days.
The average costs included $2,090 for wound or sup-
portive dressings, $65 for oral and IV antibiotics, $340
for physician or clinic visits, and institutional costs. For
cases that were already residing in LTC, the incremental
institutional cost over the pre-existing care was $7,917,
while the cost of institutional care that was fully attribut-
able to DFU (with zero pre-existing care) was $18,530.
This resulted in the total cost of DFU in existing LTC
residents of $10,413, while the full attribution costs for
new admissions to LTC was $21,025, under the assump-
tion of no time loss for caregivers.
Nationally, from the records for admissions/visits,
there were 21.9% cases that indicated the use of home
care, and a separate 13.9% had a residency status of
LTC, of which 4.3% were existing LTC residents, and
9.6% were new to LTC. Applying the average costs of
home care and LTC, this represents an additional $125.4 M
for home care, $51.7 M for existing LTC residents, and
$11.4 M for new LTC residents, for a total annual cost
of $547.0 M for DFU in Canada (Table 3). Based on a
prevalence of 25,597 cases in the year 2011, this repre-
sents $21,371 per prevalent case.
Incident cohort analysis
5,015 cases in Ontario were identified that were incident
in FY2008/2009 with their care followed for FY2008/
2009, FY2009/2010 and FY2010/2011. The average age
was 68 years (SD = 14, min = 19, max = 102) and 60% were
men (Additional file 1: Table S9). The most common co-
morbidities were diseases of the arteries and capillaries
(29%), renal failure (25%), ischemic heart disease (22%),
and heart failure (20%). The cohort was followed for up to
three years, however, 1,325 deaths occurred during this
time for a Kaplan Meier estimate of mortality of 26.4%.
Of the 5,015 incident cases, with all cases identified
by having an admission/visit in the first year, 59.3%
had admissions for any reason in the second year (33%
relevant) and 47.3% had admissions/visits for any reason inthe third year (22% relevant) (Additional file 1: Table S10).
Amputations occurred in 17.6% of the cases in the
first year, 7.3% in second year, and 3.7% in third year
(Additional file 1: Table S11). The acute care cost was
$13,031 in the first year, $5,314 in year 2 and $3,040 in
year 3 (Table 4). Overall, home care was the largest
contributor to 3-year costs ($20,180 or 39%) followed
by acute care admissions ($18,957 or 36%). The 3-year
average cost of an incident case was $52,360, of which
$26,380 (49%) occurred in year 1, $15,063 (28%) in
year 2, and $11,544 (22%) in year 3.
Discussion
In 2011, the estimated number of prevalent cases of
DFU in Canada was 25,597 rising over the 5 year period
at a rate of 7.4% growth per year. The cost associated
with each new DFU case over the first 3 years for a case
that had an admission or ER/clinic visit was $52,360,
which includes admissions, ER and clinic visits, drugs,
wounds and supportive dressings, nursing-provided
home care, LTC and caregiver time loss. In 2011, DFU
was associated with 16,863 admissions, resulting in
327,140 hospital bed days. This translates into a rate of
hospitalization for DFU of 88 per 100,000 adults, which
is similar to the rate of admissions for stroke of 124 per
100,000 adults [15].
While the use of national administrative databases have
allowed us to capture many DFU cases, the true number
of cases may be higher due to the limitations around DFU
coding in the current databases for follow-up care. Even
though the care received beyond 3 years post-initial
diagnosis may be DFU-related, such as having dressing
changes or amputations, cases without a DFU code were
not included in the estimates. By including the percent-
age of cases that was considered to have received rele-
vant DFU care, the true prevalence was estimated to be
15.6% higher. In addition, the true prevalence may even
be higher if we could include less severe diabetic foot
wounds (i.e. Wagner Grade 1 or non-urgent cases of
Wagner Grade 2) that were under physician care and
did not have a recent admission or an ER visit. Similarly,
access to hospital-based wound care clinics was gath-
ered through the NACRS database, however 39% of
wound care teams across Ontario are not located within
out-patient departments associated with hospitals [16].
Our estimates of rates of prevalence and incidence are
reported relative to the general population. If we had
recent rates of prevalence of diabetes, we could estimate
the rates of DFU relative to the diabetic population, as
well as providing a lifetime risk of DFU using cross-
sectional methods.
In recent years, there may have been factors that con-
tributed to increased cost per patient and total cost.
There have been additions to the treatment options for
Table 4 Average 3-year cumulative cost for incident DFU cases, by year, 2009–2011 (2011 CAD$)
Type of care Year 1 Year 2 Year 3 3-year cost
Acute institutional care
Admissions $11,492 $4,766 $2,699 $18,957
ER visits $370 $122 $88 $580
Procedures $746 $321 $154 $1,221
Subtotal – acute $13,031 $5,314 $3,040 $20,758
Non-acute care by residency status, (%)
At Home (no LTC, no home care) $0 (32.9%) $0 (49.3%) $0 (55.8%) $0
New to long-term care $3,568 (17.0%) $2,505 (11.9%) $1,761 (8.4%) $7,835
Resides in long-term care $1,245 (12.0%) $1,237 (11.9%) $1,104 (10.6%) $3,587
Used home care: $8,535 (38.2%) $6,006 (26.9%) $5,639 (25.2%) $20,180
Home care - direct medical $3,791 $2,668 $2,505 $8,964
informal caregiver $4,744 $3,338 $3,134 $11,217
Subtotal - non-acute $13,349 (100%) $9,749 (100%) $8,504 (100%) $31,602
Total cost $26,380 $15,063 $11,544 $52,360
Total Cost - direct medical $21,212 $11,619 $8,312 $41,143
Total Cost - informal care $4,744 $3,338 $3,134 $11,217
Index year for incidence cohort was 2009, with previous 2 years without DFU diagnosis in any record.
Costs exclude outpatient billings for non-home care and non-LTC cases.
59% of cohort had year 2 costs, 47% of cohort had year 3 costs.
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of health care, including new bioactive gauzes, and an
increased focus to increase the blood flow to the foot
with peripheral vascular surgery in order to save the
limb to prevent amputation. Both of these factors may
have contributed to increased intensity of DFU care,
while the factors may also have increased the duration of
care for DFU. In addition to more treatment options,
there has been an increased focus to intervene earlier in
the progression of DFU by treating Wager grade 1 or 2
wounds. Also, there is a high rate of mortality for patients
with DFU which suggests there would be increased re-
source intensity with severe cases to prevent death.
In addition to capturing most cases of DFU, multi-
faceted costs of DFU-related care were identified over
many years, such as osteomyelitis, angiopathy, amputa-
tion and complications. Based on our analysis, 22% of
incident cases had a DFU-related admission or ER visit
at 3 years after the first admission. Estimates from previ-
ous work emphasized DFU without an amputation, or
focused on amputations only. For example, for the first
year of DFU without an amputation, based on literature
values from the United States in 2013, the cost of DFU
care was $2,147, and a separate cost was $9,041 if an
amputation was involved [17]. For Medicare patients
in the United States, the 12-month cost for DFU that
excluded drug costs and caregiver or patient work loss
was $11,296 [18]. A literature review for international
estimates was reported in the Lancet in 2005 and the
only evidence that was available at the time was fromsmall case series [19]. Ontario multi-year period estimates
that have focused on amputation including admissions,
ER visits and drugs, but excluding home care and LTC,
provided estimates of $34,470 for the first year of an am-
putation and $4,721 for all subsequent years [20]. Based
on this project’s estimates, the added costs of home care
and LTC represent an additional 41%.
This analysis included several key components (e.g.,
multi-year patient-level data in many administrative
datasets; national and provincial data), however several
limitations are to be noted. First, the number of cases
was based on two extrapolations: the added cases that
arise from ER and clinic visits, and the extrapolation to
the provinces with missing data (i.e. British Columbia
and Quebec accounting for 40% of the national popula-
tion). Based on the variation that exists across provinces,
we might expect that the extrapolated costs to the miss-
ing provinces could be different by +/− 11% for women
and +/− 8% for men. Second, although the most respon-
sible diagnosis was used at discharge to identify the
study population, some of the days spent in hospitals
may be have been related to other conditions. Similarly,
for the home care and LTC cost per incident cases were
used that had only DFU and cases with pressure ulcers
were excluded to derive an average cost for health care.
As such, it may be that the cost to treat DFU ulcers is
higher due to increased comorbidity, or lower due to
coupled care. Similarly, our costs are based on a unique
patient, and each patient may have experienced multiple
DFU. A third limitation is the percentage of the cost of
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that is attributed to DFU. We acknowledge that the
presence of other comorbidities will increase the cost
for each episode and increase the probability of an
admission/visit. In the health economics literature, 3
methods have been proposed to account for attribution
bias. The first is selective attribution, which is to be
parsimonious in choosing health care that is disease-
related, which is the approach we have taken here by
requiring an admission to have an associated intervention.
The second method is to conduct a pre-post analysis to
estimate the annual cost of patients with diabetes before
and after a DFU diagnosis. A third and more common
method is to use matching or regression methods where
patients with diabetes are stratified by presence or absence
of DFU. The difference between the annual cost of the pa-
tients is then fully attributed to DFU. Both of these latter
2 methods, as well as any regression adjustment should
include a larger dataset than we obtained. Future work
should include estimating the attribution percentage from
using either method, and to explain factors that contribute
to variation in costs.
Conclusion
In conclusion, the burden associated with DFU in Canada
in 2011 was estimated to be $547.0 M. As shown in this
sensitivity analysis, when including cases that had DFU-
related care, (despite not having a DFU code), the annual
cost might be 16% higher, and the cost of acute care could
be 17% higher if we included admissions without disease-
related interventions. Since our trend over 5 years was a
7.4% increase in the rate of prevalence, the cost of DFU
could increase in the future. As such, improved manage-
ment of diabetes, prevention and early treatment of DFUs
are essential to decrease the human and economic burden
of DFU. In 2012 The Council of the Federation, the na-
tional and provincial premiers in Canada, recommended
that the healthcare systems prioritize interventions that
slow or halt the progression of diabetes complications [21].Additional file
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